Deciphera Pharmaceuticals
Waltham, US · Founded 2015 · Delaware LLC · 547 employees on LinkedIn · 4 known investors
Find your way into Deciphera Pharmaceuticals
Sign up to see every warm intro you have to Deciphera Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Deciphera Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Develops selective kinase inhibitors for cancer (QINLOCK); acquired by Ono Pharmaceuticals in 2024.
Founders & leadership
Deciphera Pharmaceuticals was founded in 2015 by Daniel F. Flynn, Ph.D..


Board
Investors · 4
How we know: Frazier Life Sciences's portfolio page · Not right? Tell us
How we know: Viking Global's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$142.9M disclosed across 2 rounds · 2015–2017
▶$52.3MraisedJun 2017 · 7 investors · BiotechnologyRule 506(b)
- Michael RossDirector
- Oliver Rosen, M.D.Executive Officer
- Thomas KellyExecutive Officer
- Patricia L. AllenDirector
- John MartinDirector
- Daniel L. Flynn, Ph.D.Executive Officer
- Dennis WalshDirector
- James A. Bristol, Ph.D.Director
- Christopher MorlExecutive Officer
- Michael D. Taylor, Ph.D.Executive Officer, Director
- Liam Ratcliffe, M.D., Ph.D.Director
- Edward J. Benz, Jr.Director
- Offering amount
- $52.3M
- Amount sold
- $52.3M
- First sale
- May 2017
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
▶$90.6MraisedJul 2016 · 5 investors · PharmaceuticalsRule 506(b)
- Michael RossDirector
- Oliver Rosen, M.D.Executive Officer
- Thomas KellyExecutive Officer
- John MartinDirector
- Daniel F. Flynn, Ph.D.Executive Officer
- Liam Ratcliffe, M.D., Ph.D.Director
- Michael TaylorExecutive Officer, Director
- James A. Bristol, Ph.D.Director
- Dennis WalshDirector
- Offering amount
- $90.6M
- Amount sold
- $90.6M
- First sale
- Sep 2015
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Deciphera Pharmaceuticals do?
- Develops selective kinase inhibitors for cancer (QINLOCK); acquired by Ono Pharmaceuticals in 2024.
- Who founded Deciphera Pharmaceuticals?
- Deciphera Pharmaceuticals was founded by Daniel F. Flynn, Ph.D. in 2015.
- Who are Deciphera Pharmaceuticals's investors?
- Deciphera Pharmaceuticals's investors include Frazier Life Sciences, Viking Global, REDMILE, Viking Global Investors.
- How much funding has Deciphera Pharmaceuticals raised?
- Deciphera Pharmaceuticals has disclosed $142.9M raised across 2 rounds.
- Where is Deciphera Pharmaceuticals headquartered?
- Deciphera Pharmaceuticals is headquartered in Waltham, US.
